Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small interfering RNA (KDM4B)
- Development stage
- Preclinical
- Lead developer
- Sungkyunkwan University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
small interfering RNA (KDM4B) is an experimental RNA interference (RNAi) agent designed to silence the expression of the histone lysine demethylase 4B (KDM4B). KDM4B is an epigenetic co-activator of estrogen receptor alpha (ERα) signaling and is frequently overexpressed in breast cancer, contributing to tumor progression and endocrine resistance. By targeting KDM4B mRNA for degradation, this siRNA restores repressive H3K9me3 histone marks, downregulates ERα expression, and induces G1/S cell-cycle arrest. Research indicates that KDM4B knockdown also attenuates glycolytic activity, suggesting a role in metabolic reprogramming. It is primarily being investigated as a therapeutic strategy to overcome resistance to endocrine therapies like tamoxifen in ERα-positive breast cancer.
- Other names
- KDM4B siRNAKDM-4B siRNAKDM 4B siRNAsi-KDM4Bsi-KDM-4Bsi-KDM 4B
02
Targets
KDM4 (KDM4 family)
Beyond the preview
Go deeper on small interfering RNA (KDM4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small interfering RNA (KDM4B).